uniQure (NASDAQ:QURE) Posts Quarterly Earnings Results, Beats Estimates By $0.37 EPS

uniQure (NASDAQ:QURE) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.93) by $0.37, FiscalAI reports. The business had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%.

uniQure Trading Down 8.6%

QURE opened at $15.63 on Monday. The firm’s fifty day moving average is $23.46 and its two-hundred day moving average is $29.80. The firm has a market cap of $973.62 million, a PE ratio of -3.56 and a beta of 0.66. uniQure has a twelve month low of $7.76 and a twelve month high of $71.50. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Unusual bullish options flow — heavy call buying (24,345 calls, ~181% above typical volume) suggests some traders are speculating on a near‑term rebound or event‑driven move.
• Negative Sentiment: Fresh FDA controversy: coverage highlights critical comments from FDA leadership about uniQure’s rejected rare‑disease therapy, which markets see as increasing regulatory risk for the program. uniQure: Shares Tumble On Fresh FDA Controversy – What Investors Should Know
• Negative Sentiment: FDA commissioner comments drew broad media coverage and were cited as the main driver of the selloff, amplifying short‑term downside as investors reassess approval odds. UniQure plummets as FDA’s Marty Makary disparages rejected rare disease drug
• Negative Sentiment: Multiple securities‑class action filings and firm notices: several law firms are publicizing suits or seeking lead plaintiffs for alleged misstatements during a specified class period — increasing legal and reputational risk and likely weighing on sentiment. Representative notices: DJS Law Group. uniQure N.V. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – QURE
• Negative Sentiment: Broad wave of law‑firm alerts and reminder notices (Rosen, Pomerantz, Faruqi, Robbins, Berger Montague, etc.) highlights that litigation momentum is building and that April 13, 2026 lead‑plaintiff deadlines are approaching — an added near‑term overhang. Example: Rosen Law Firm reminder. ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action – QURE
• Negative Sentiment: Market reaction summaries: analyst/news pieces attribute a large intraday drop to the FDA remarks and resulting uncertainty, reinforcing negative sentiment. Why Is uniQure Stock Down 30% Today?

Insider Activity

In related news, Director Robert Gut sold 25,613 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the sale, the director owned 32,342 shares in the company, valued at $796,260.04. This represents a 44.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Matthew C. Kapusta sold 12,378 shares of uniQure stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $23.86, for a total value of $295,339.08. Following the transaction, the chief executive officer owned 639,076 shares in the company, valued at approximately $15,248,353.36. This represents a 1.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 50,598 shares of company stock worth $1,248,588 over the last quarter. Corporate insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

A number of large investors have recently bought and sold shares of QURE. Smartleaf Asset Management LLC acquired a new stake in uniQure during the 4th quarter worth approximately $48,000. CIBC Private Wealth Group LLC bought a new stake in shares of uniQure during the third quarter worth $50,000. Ensign Peak Advisors Inc increased its position in shares of uniQure by 21.7% during the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock worth $87,000 after acquiring an additional 650 shares in the last quarter. Knott David M Jr lifted its position in uniQure by 100.0% in the 4th quarter. Knott David M Jr now owns 4,000 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in uniQure by 358.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 5,538 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

QURE has been the subject of several recent research reports. Chardan Capital reissued a “buy” rating and set a $53.00 price objective on shares of uniQure in a report on Thursday, December 4th. William Blair reissued a “market perform” rating on shares of uniQure in a research note on Tuesday, November 11th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of uniQure in a research note on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of uniQure in a report on Wednesday, January 21st. Finally, Stifel Nicolaus cut their price target on uniQure from $50.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday, December 11th. Ten analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, uniQure presently has an average rating of “Moderate Buy” and an average target price of $58.33.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.